Um Novo Olhar sobre a Telangiectasia Macularis Eruptiva Perstans
Resumo
A telangiectasia macularis eruptiva perstans (TMEP) é uma forma rara de mastocitose cutânea com semiologia e histologia próprias, mas não isenta de controvérsia em relação à sua individualização enquanto entidade nosológica. Para alguns autores, a presença exclusivamente de lesões maculosas telangiectásicas a par de dilatação do plexo vascular superficial e de infiltrados mastocitários pouco densos na derme superficial é suficiente para o diagnóstico de TMEP. Ainda assim, em algumas classificações vigentes esta entidade não é considerada separadamente de outras formas de mastocitose cutânea, pois em muitos casos com lesões telangiectásicas também se podem observar lesões de urticária pigmentosa. Nós apresentamos um caso de mastocitose cutânea com características clínicas, dermatoscópicas e histológicas compatíveis com TMEP, de aparecimento na oitava década de vida e sem outros sintomas de ativação mastocitária, além do prurido. Porém, o estudo complementar revelou a presença concomitante de mastocitose sistémica indolente. Adicionalmente, revimos a evidência mais recente a favor do reconhecimento e individualização desta entidade.
Downloads
Referências
Horny H, Metcalfe D, Bennett J. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri AS, editors)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues .4th ed. Lyon: International Agency of Research and Cancer (IARC); 2008.
Maluf LC, Barros JA, Machado Filho CD. Mastocitose. An Brasil Dermatol. 2009; 84: 213-25.
Sarkany RPE, Monk BE, Handfield-Jones SE. Telangiectasia macularis eruptiva perstans: a case report and
review of the literature. Clin Exp Dermatol.1998; 23:38-9.
Marrouche N, Grattan C. TMEP or not TMEP: That is the question. J Am Acad Dermatol. 2014; 70:581-2.
Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016; 137:35-45.
Akay BN, Kittler H, Sanli H, Harmankaya K, Anadolu R. Dermatoscopic findings of cutaneous mastocytosis. Dermatology.
; 218:226-30.
Berezowska S, Flaig MJ, Rueff F, Walz C, Haferlach T, Krokowski M, et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol. 2014; 27:19-29.
Fraitag-Spinner S. Mastocytoses cutanées. Ann Dermatol Vénéréol. 2007; 134:589-92.
Ackerman AB. Urticaria Pigmentosa. In: Ackerman AB, editor. Histologic diagnosis of inflammatory skin diseases.
An algorithmic method based on pattern analysis Baltimore: Williams and Wilkins; 1997.p. 887-1.
Severino M, Chandesris M-O, Barete S, Tournier E, Sans B, Laurent C, et al.. Telangiectasia macularis eruptiva
perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. J Am Acad Dermatol. 2016; 74:885-91.
Martin-Fuentes A, Pastor-Nieto MA, De Eusebio-Murillo E. Telangiectatic macules in a 90-year-old woman. Actas
Dermosifiliogr. 2012; 103:65-6.
Fernandes IC, Teixeira MA, Freitas I, Selores M, Alves R, Lima M. Adult mastocytosis: a review of the Santo António
Hospital 's experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease. An Brasil Dermatol. 2014; 89:59-66.
Macias VC, Amaro C, Freitas I, Vieira R, Cardoso J. Mastocitose cutânea na infância – estudo retrospetivo de 32 doentes. Rev Soc Port Dermatol Venereol. 2013;70:5.
Weber FP, Hellenschmied R. Telangiectasia macularis eruptiva perstans. Br J Dermatol. 1930; 42:374-82.
Weber FP. Urticaria pigmentosa in an adult. Proc R Soc Med. 1930; 24:95-6.
Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and
adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003; 48:508-16.
Escribano L, Álvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients J Allergy ClinImmunol. 2009; 124:514-21.
Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al.. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108:2366-72.
Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, et al. Phase II study of imatinib
mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009; 33: 1481-4.
Watkins CE, Bokor WB, Leicht S, Youngberg G, Krishnaswamy G. Telangiectasia macularis eruptiva perstans:
more than skin deep. Dermatol Reports. 2011; 3: e12.
Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to
manage). Blood. 2013; 121:3085-94.
Lim KH, Pardanani A, Butterfield JH, Li C-Y, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis:
Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009; 84:790-4.
Todos os artigos desta revista são de acesso aberto sob a licença internacional Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0).
